Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

NCT00050596 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: MDX-010 / MDX-010 + Docetaxel

Sponsor

Bristol-Myers Squibb